Opportunity

Simpler Grants.gov #PAR-25-075

Clinical Validation of Cancer Assays and Markers for NCI Studies

Buyer

National Institutes of Health

Posted

October 15, 2024

Respond By

October 14, 2026

Identifier

PAR-25-075

NAICS

541380, 541715

This opportunity from the National Cancer Institute (NCI) seeks to accelerate the clinical validation of established molecular, cellular, and imaging assays and markers for cancer research. - Government Buyer: - National Institutes of Health (NIH), National Cancer Institute (NCI) - Products/Services Requested: - Clinical validation of analytically validated assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of treatment response or resistance - Includes pharmacodynamic and toxicity markers - Focus on harmonizing laboratory tests across multiple clinical laboratories - Use of specimens from retrospective or prospective clinical trials or studies - Requirements: - Applicants must already have analytically validated assays in relevant specimen types - Multidisciplinary collaboration required (scientific investigators, oncologists, statisticians, clinical laboratory scientists) - No support for early-stage technology development or direct conduct of clinical trials - Goal is to prepare assays for integration into clinical studies - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation

Description

The National Cancer Institute (NCI) seeks to accelerate the adoption and validation of molecular, cellular, and imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of treatment response or resistance. This funding opportunity supports the clinical validation of established assays for up to 3 years using specimens from clinical trials or studies, including efforts to harmonize clinical laboratory tests across multiple labs. The NOFO is intended for validation of assays to the point where they can be integrated into clinical trials or studies, not for early-stage technology development or conducting clinical trials. Projects require multidisciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists.

View original listing